We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blocking the Thromboxane Receptor Prevents Alzheimer's Disease in Mouse Model

By LabMedica International staff writers
Posted on 30 Nov 2014
A recent study carried out on a transgenic mouse model of Alzheimer's disease identified the thromboxane receptor (TP) as an active contributor to the development of the disease and a feasible target for drugs to treat it.

Investigators at Temple University (Philadelphia, PA, USA) had reported previously that 8-isoprostaneF2alpha (8ISO)—a marker for lipid oxidation and an indicator of oxidative stress—increased brain amyloid-beta levels and deposition in the Tg2576 mouse Alzheimer's disease model.

In the current study, the investigators continued this line of research by examining how (8ISO) affected behavior and tau protein metabolism. More...
To this end, they characterized the behavioral, biochemical, and neuropathologic effects of 8ISO in the triple transgenic mouse model.

They reported in the October 10, 2014, online edition of the journal Neurobiology of Aging that compared with controls, the transgenic mice receiving 8ISO showed significant memory deficits, increase in tau phosphorylation, activation of the cyclin kinase-5 pathway, and neuroinflammation. All these effects could be prevented by treatment with drugs that blocked the thromboxane receptor, a G-protein coupled receptor coupled to the G protein Gq.

“Besides the two major signature brain pathologies associated with Alzheimer’s disease, amyloid beta plaques and the tangles which are formed from the phosphorylation of the tau protein, researchers have also known for a while that there is a signature from oxidation stress,” said senior author Dr. Domenico Praticò, professor of pharmacology, microbiology, and immunology in Temple University. “But it has always been believed that oxidative stress was just a bystander and did not have an active function in the development of the disease.”

“For the first time we have identified this receptor as the culprit responsible for the bad things that happen with the disease when high levels of oxygen free radicals are produced,” said Dr. Praticò. “Basically, it sends the wrong message inside the neuronal cells, and with time, this definitely will result in all the clinical manifestations of the disease, such as cognitive impairment, loss of memory, and brain cell death. This indirectly confirmed for us that the free radicals worked through this receptor.”

Related Links:

Temple University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.